USPTO serial 87814862
CHAI
Reviewed by CopyMark Law Group
Reg. 5962171Status 713
- Filing date
- Status date
- Registration date
- Jan 14, 2020
- Examiner
- TANNER, MICHAEL R
- Law office
- TTAB
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with CHAI?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Santa Clara, CA, US
Santa Clara, CA, US
SANTA CLARA, CA, US
SANTA CLARA, CA, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
CHAI INC.
990 RICHARD AVENUESUITE 110SANTA CLARA, CA 95050Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Reagents for use in gene analysis and sequencing as well as DNA and RNA analysis and sequencing, namely, polymerase chain reaction (PCR) master mixes, polymerase chain reaction (PCR) reagents and enzymes, polymerase chain reaction (PCR) test kits containing DNA primers and template control DNA for polymerase chain reaction (PCR), all for scientific and medical research use; Reagents for use in scientific apparatus for chemical or biological analysis; Reagents for in vitro use in biochemistry and cell culture reagents for scientific and research use; Reagents for scientific and research use used in the collection, storage and preparation of materials for gene analysis and sequencing as well as DNA and RNA analysis and sequencing, and in DNA extraction systems for crude lysates, DNA purification systems and cell filtration systems; Biochemical reagents used for non-medical purposes; Reagents for use in scientific apparatus for chemical or biological analysis; Reagents for in vitro use in biochemistry and microbiology; Cell culture reagents for scientific and research use; Reagents for scientific or research use used in detecting pathogens and genetic mutations, namely, test kits for laboratory or research use containing one or more of polymerase chain reaction (PCR) reagents, polymerase chain reaction (PCR) primers, cell culture medias, biochemical reagents used for non-medical purposes, reagents for use in scientific apparatus for chemical or biological analysis, reagents for in vitro use in biochemistry and clinical microbiology, and cell culture reagents for scientific and research use; Reagents and consumables for scientific or research use used in connection with polymerase chain reaction (PCR), molecular diagnostics, and gene analysis, namely, polymerase chain reaction (PCR) master mixes, quantitative polymerase chain reaction (qPCR) master mixes, polymerase chain reaction (PCR) reagents comprising polymerase enzymes, deoxynucleotides (dNTPs), aptamer and antibody hot start mechanisms, reverse-transcription enzymes, biochemical reagents used for non-medical purposes, reagents for use in scientific apparatus for biological analysis, and cell culture reagents all for scientific and research use | SECTION 18 - CANCELLED | Mar 30, 2017 |
| 005 | Reagents for medical diagnostic use used in gene analysis and sequencing as well as DNA and RNA analysis and sequencing, namely, polymerase chain reaction (PCR) master mixes, polymerase chain reaction (PCR) reagents and enzymes, polymerase chain reaction (PCR) test kits containing DNA primers and template control DNA for polymerase chain reaction (PCR), all for medical diagnostic use, diagnostic biomarker reagents for medical purposes, diagnostic reagents for medical use, medical diagnostic reagents for the analysis of body fluids, medical diagnostic reagents and assays for testing body fluids for microorganisms, and diagnostic reagents and assays for diagnostic testing of medical samples for microorganisms, pathogens, genotypes, and viruses; Reagents for medical diagnostic use used in the collection, storage and preparation of materials for gene analysis and sequencing as well as DNA and RNA analysis and sequencing, and in DNA extraction systems for crude lysates, DNA purification systems and cell filtration systems, diagnostic biomarker reagents for medical purposes, diagnostic reagents for medical use, medical diagnostic reagents for the analysis of body fluids, and medical diagnostic reagents and assays for testing body fluids for microorganisms; Reagents for medical diagnostic use used in detecting pathogens and genetic mutations, namely, test kits for medical diagnostic use containing one or more of polymerase chain reaction (PCR) reagents, polymerase chain reaction (PCR) primers, cell culture medias, and diagnostic reagents and assays for diagnostic testing of medical samples for microorganisms, pathogens, genotypes, and viruses; Reagents and consumables for medical diagnostic use used in connection with polymerase chain reaction (PCR), molecular diagnostics, and gene analysis, namely, polymerase chain reaction (PCR) master mixes, quantitative polymerase chain reaction (qPCR) master mixes, polymerase chain reaction (PCR) reagents comprising polymerase enzymes, deoxynucleotides (dNTPs), aptamer and antibody hot start mechanisms, and reverse-transcription enzymes, all for medical diagnostic use | SECTION 18 - CANCELLED | Mar 30, 2017 |
| 009 | DNA amplification apparatus, namely, thermocyclers for scientific or medical research use; downloadable software for use with thermocyclers and DNA amplification devices for use in operating and controlling quantitative polymerase chain reaction (qPCR) thermocyclers, for use in conducting analysis of real-time polymerase chain reaction (PCR) and quantitative polymerase chain reaction (qPCR) data including amplification curve analysis, Cq calling, melt curve analysis, high resolution melt (HRM) quantification, and for use in test kit analysis for conducting presence and absence analysis, quantitative analysis, and analysis of control reactions; downloadable software for use in DNA and RNA analysis and sequencing, detection of genetic mutations, and detection of pathogens; downloadable software for gene analysis and sequencing, DNA and RNA analysis and sequencing, and identification of pathogens, allergens, bacteria, organisms, mold, plants, food, and biowarfare agents for use in medical diagnosis and treatment, scientific research and development, education, medical testing, veterinary diagnostics, food safety testing, water quality testing, beer quality testing, DNA tracing, food fraud prevention, and biosecurity | SECTION 18 - CANCELLED | Jul 14, 2014 |
| 010 | DNA amplification apparatus, namely, thermocyclers for DNA and RNA testing for medical purposes | SECTION 18 - CANCELLED | Jul 14, 2014 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Chai Biotechnologies Inc.
- Other trademarks owned by Chai Biotechnologies Inc.
- Other trademarks owned by CHAI INC.
- Other trademarks owned by CHAI INC.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 010
- Similar marks named CHAI
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 14, 2026 | C18. | CANCELLED SECTION 18-TOTAL | — |
| Jul 14, 2026 | CANT | CANCELLATION TERMINATED NO. 999999 | — |
| May 27, 2026 | CANG | CANCELLATION GRANTED NO. 999999 | — |
| Jan 15, 2026 | PETC | CANCELLATION INSTITUTED NO. 999999 | — |
| Oct 16, 2025 | WOAG | WITHDRAWAL OF ATTORNEY GRANTED | — |
| Oct 16, 2025 | WOAR | TEAS WITHDRAWAL OF ATTORNEY RECEIVED | — |
| Jan 14, 2025 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Jan 14, 2020 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Dec 13, 2019 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| Dec 12, 2019 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Nov 22, 2019 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Nov 22, 2019 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Nov 20, 2019 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Nov 13, 2019 | IUAF | USE AMENDMENT FILED | — |
| Nov 13, 2019 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| May 14, 2019 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Mar 19, 2019 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 19, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 27, 2019 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Feb 8, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 16, 2019 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jan 16, 2019 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jan 16, 2019 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jan 16, 2019 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jan 11, 2019 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jan 11, 2019 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jan 11, 2019 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jan 11, 2019 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Dec 18, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 18, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 14, 2018 | ALIE | ASSIGNED TO LIE | — |
| Dec 11, 2018 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 18, 2018 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 18, 2018 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 18, 2018 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 12, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 7, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 3, 2018 | NWAP | NEW APPLICATION ENTERED | — |